Analyst Price Targets — AVEO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2022 12:00 am | Stephen Willey | Stifel Nicolaus | $14.00 | $5.66 | Pulse 2.0 | AVEO Pharmaceuticals (AVEO) Stock: $14 Price Target And Buy Rating |
Latest News for AVEO
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan,…
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVEO.
U.S. House Trading
No House trades found for AVEO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.